Skip to main content
Have a personal or library account? Click to login
Uric Acid Target Achievement and Factors Associated with Treatment Outcomes in Gout: A Retrospective Study from a Tertiary Rheumatology Centre Cover

Uric Acid Target Achievement and Factors Associated with Treatment Outcomes in Gout: A Retrospective Study from a Tertiary Rheumatology Centre

Open Access
|Jun 2026

References

  1. Charoenngam, N., Ponvilawan, B., Ungprasert, P. (2020). Vitamin D insufficiency and deficiency are associated with a higher level of serum uric acid: A systematic review and meta-analysis. Mod. Rheumatol., 30 (2), 385–390. https://pubmed.ncbi.nlm.nih.gov/30689484/. DOI: 10.1080/14397595.2019.1575000.
  2. Choi, H. G., Kwon, B. C., Kwon, M. J., Kim, J. H., Park, B., Lee, J. W. (2022). Association between gout and dyslipidemia: A nested case-control study using a national health screening cohort. J. Pers. Med., 12 (4), 605. https://pmc.ncbi.nlm.nih.gov/articles/PMC9032264/. DOI: 10.3390/jpm12040605.
  3. Faruque, L. I., Ehteshami-Afshar, A., Wiebe, N., Tjosvold, L., Homik, J., Tonelli, M. (2013). A systematic review and meta-analysis on the safety and efficacy of febuxostat versus allopurinol in chronic gout. Semin. Arthritis Rheum., 43 (3), 367–375. https://pubmed.ncbi.nlm.nih.gov/24326033/. DOI: 10.1016/j.semarthrit.2013.05.004.
  4. FitzGerald, J. D. (2025). Gout. Ann. Intern. Med., 178 (3), ITC33–ITC48. https://pubmed.ncbi.nlm.nih.gov/40063960/. DOI: 10.7326/ANNALS-24-03951.
  5. FitzGerald, J. D., Dalbeth, N., Mikuls, T., Brignardello-Petersen, R., Guyatt, G., Abeles, A. M., Gelber, A. C., Harrold, L. R., Khanna, D., King, C., et al. (2020). 2020 American College of Rheumatology guideline for the management of gout. Arthritis Care Res., 72 (6), 744–760. https://assets.contentstack.io/v3/assets/bltee37abb6b278ab2c/blt04d52e3b6ff5112f/632cab5b258fb55f6b2186af/gout-guideline-2020.pdf. DOI: 10.1002/acr.24180.
  6. Han, Y., Han, X., Zhao, H., Yao, M., Xie, T., Wu, J., Zhang, Y., Zeng, X. (2025, April). The exploration of the relationship between hyperuricemia, gout, and vitamin D deficiency. J. Nutr. Biochem., 138, 109848. https://doi.org/10.1016/j.jnutbio.2025.109848.
  7. Kannuthurai, V., Gaffo, A. (2023). Management of patients with gout and kidney disease: A review of available therapies and common mis-steps. Kidney360, 4 (9), e1332–e1340. https://journals.lww.com/kidney360/fulltext/2023/09000/management_of_patients_with_gout_and_kidney.22.aspx. DOI: 10.34067/KID.0000000000000221.
  8. Kim, A., Kim, Y., Kim, G. T., Ahn, E., So, M. W., Lee, S. G. (2020). Comparison of persistence rates between allopurinol and febuxostat as first-line urate-lowering therapy in patients with gout: An 8-year retrospective cohort study. Clin. Rheumatol., 39 (12), 3769–3776. https://pubmed.ncbi.nlm.nih.gov/32458236/. DOI: 10.1007/s10067-020-05161-w.
  9. Richette, P., Doherty, M., Pascual, E., Barskova, V., Becce, F., Castañeda-Sanabria, J., Coyfish, M., Guillo, S., Jansen, T. L., Janssens, H., et al. (2017). 2016 updated EULAR evidence-based recommendations for the management of gout. Ann. Rheum. Dis., 76 (1), 29–42. https://pubmed.ncbi.nlm.nih.gov/27457514/. DOI: 10.1136/annrheumdis-2016-209707.
  10. Roddy, E., Choi, H. K. (2014). Epidemiology of gout. Rheum. Dis. Clin. North Am., 40 (2), 155–175. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4119792/. DOI: 10.1016/j.rdc.2014.01.001.
  11. Scheepers, L. E. J. M., van Onna, M., Stehouwer, C. D. A., Singh, J. A., Arts, I. C. W., Boonen, A. (2018). Medication adherence among patients with gout: A systematic review and meta-analysis. Semin. Arthritis Rheum., 47 (5), 689–702. https://doi.org/10.1016/j.semarthrit.2017.09.007.
  12. Sinnappah, K. A., Stocker, S. L., Chan, J. S., Hughes, D. A., Wright, D. F. B. (2022). Clinical interventions to improve adherence to urate-lowering therapy in patients with gout: A systematic review. Int. J. Pharm. Pract., 30 (3), 215–225.: https://academic.oup.com/ijpp/article/30/3/215/6568062. DOI: 10.1093/ijpp/riac025.
  13. Xie, H., Hu, N., Pan, T., Wu, J. C., Yu, M., Wang, D. C. (2023). Effectiveness and safety of different doses of febuxostat compared with allopurinol in the treatment of hyperuricemia: A meta-analysis of randomized controlled trials. BMC Pharmacol. Toxicol., 24 (1), 79. https://pubmed.ncbi.nlm.nih.gov/38098046/. DOI: 10.1186/s40360-023-00723-5.
DOI: https://doi.org/10.2478/prolas-2026-0023 | Journal eISSN: 2255-890X | Journal ISSN: 1407-009X
Language: English
Page range: 247 - 251
Submitted on: Oct 13, 2025
Accepted on: Mar 17, 2026
Published on: Jun 29, 2026
In partnership with: Paradigm Publishing Services

© 2026 Hanna Marta Hansone, Anna Mihailova, published by Latvian Academy of Sciences
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.